Cell-specific gene therapy driven by an optimized hypoxia-regulated vector reduces choroidal neovascularization.

Area of Science:

• Ophthalmology
• Gene Therapy
• Molecular Biology

Background:

• Choroidal neovascularization (CNV) is a key feature of exudative age-related macular degeneration (AMD), leading to blindness.
• Hypoxia and hypoxia-inducible factors (HIF) are implicated in CNV development.
• Targeting hypoxic conditions in retinal pigment epithelium (RPE) offers a therapeutic strategy.

Purpose of the Study:

• To develop and test an optimized, RPE-specific gene therapy regulated by hypoxia to inhibit CNV.
• To evaluate the efficacy of AAV2-mediated delivery of endostatin in a preclinical model.

Main Methods:

• An adeno-associated virus serotype 2 (AAV2) vector was engineered with an RPE-specific promoter and HIF-1 response elements (HRE).
• The vector was designed to express human endostatin, an anti-angiogenic protein, in RPE cells.
• The vector was delivered subretinally in a laser-induced mouse model of CNV.

Main Results:

• Subretinal delivery of the AAV2 vector resulted in an 80% reduction in CNV areas compared to controls.
• Quantitative real-time polymerase chain reaction (qPCR) confirmed hypoxia-induced endostatin mRNA expression, elevated at 3, 7, and 14 days post-treatment.
• Endostatin expression was transient, shutting off after 45 days, indicating controlled therapeutic protein production.

Conclusions:

• RPE-specific, hypoxia-regulated gene therapy is a viable approach to inhibit CNV.
• This strategy offers targeted delivery of anti-angiogenic factors directly to the site of neovascularization.
• The transient and regulated expression of endostatin suggests a safe and effective therapeutic window for treating neovascular AMD.